FGFR3 mutations in bladder cancer are mostly activating, followed by gene rearrangements and amplification (Cancer Genome Atlas Research Network, 2014[1]; Helsten et al., 2016[13]). Here, FGFR3 is linked to urinary bladder carcinoma.